Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Neoplasms 3Neoplasm Metastasis 2Carcinoma, Hepatocellular 2Solid Tumors 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × brivanib × Clear all
NCT00437437 2013-06-21

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

Bristol-Myers Squibb

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

NCT00435669 2009-01-22

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Bristol-Myers Squibb

Phase 1 Completed
4 enrolled
Tumor-Agnostic

Neoplasms

NCT00207103 2008-11-04

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
68 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡